SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

Next generation sequencing of myeloid neoplasms with eosinophilia harboring theFIP1L1-PDGFRAmutation

(2016) Animesh Pardanani et al.   AMERICAN JOURNAL OF HEMATOLOGY

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors

(2016) Jiajun Wang et al.   JOURNAL OF UROLOGY

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

(2016) H Parker et al.   LEUKEMIA

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis

(2016) M Jawhar et al.   LEUKEMIA

SETD2: an epigenetic modifier with tumor suppressor functionality

(2016) Jun Li et al.   Oncotarget

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis

(2015) S. Barete et al.   BLOOD

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

(2015) Sophia X. Pfister et al.   CANCER CELL

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

(2015) M Jawhar et al.   LEUKEMIA

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis

(2015) M Arock et al.   LEUKEMIA

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

(2015) M Jawhar et al.   LEUKEMIA

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma

(2015) Weisi Liu et al.   MEDICINE

Mast Cells, Mastocytosis, and Related Disorders

(2015) Theoharis C. Theoharides et al.   NEW ENGLAND JOURNAL OF MEDICINE

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair

(2015) N Kanu et al.   ONCOGENE

Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases

(2015) Martin Chopra et al.   Cancer Genetics

Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis

(2014) Celalettin Ustun et al.   JOURNAL OF CLINICAL ONCOLOGY

Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens

(2014) M. Mayerhofer et al.   JOURNAL OF IMMUNOLOGY

Identification of functional cooperative mutations of SETD2 in human acute leukemia

(2014) Xiaofan Zhu et al.   NATURE GENETICS

Age-related mutations associated with clonal hematopoietic expansion and malignancies

(2014) Mingchao Xie et al.   NATURE MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint

(2014) Sílvia Carvalho et al.   eLife

Comprehensive mutational profiling in advanced systemic mastocytosis

(2013) J. Schwaab et al.   BLOOD

Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

(2011) M S Spector et al.   LEUKEMIA

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

(2010) Gillian L. Dalgliesh et al.   NATURE

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

(2009) K. J. Aichberger et al.   BLOOD

Heterogeneous Nuclear Ribonucleoprotein L Is a Subunit of Human KMT3a/Set2 Complex Required for H3 Lys-36 Trimethylation Activityin Vivo

(2009) Wen Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA